Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

European shares slipped on Friday after a rally in the previous session spurred by the U.S. Federal Reserve’s outsize ...

European shares slipped on Friday (Sep 20) after a rally in the previous session spurred by the US Federal Reserve’s outsized ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Women who use contraceptive pills, particularly combined oral contraceptives (COCs) containing both oestrogen and ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

However, the analysts said: “Given our own forecast that CPI inflation will rise back to 2.9pc by January next year (perhaps ...

WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all.

This post was written by Luke Carberry Mogan. Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor ...